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Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer.
Objective:Our objectivewas to investigatewhether vitamin D or calcium supplementation affects
mortality, vascular disease, and cancer in older people.
Design and Setting: The study included long-term follow-up of participants in a two by two
factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom.
Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-
trauma fracture.
Interventions:Participantswere randomlyallocated todaily vitaminD3 (800 IU), calcium(1000mg),
both, or placebo for 24–62 months, with a follow-up of 3 yr after intervention.
Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and
cancer incidence were evaluated.
Results: In intention-to-treat analyses, mortality [hazard ratio (HR)  0.93; 95% confidence interval
(CI) 0.85–1.02], vascular disease mortality (HR 0.91; 95% CI 0.79–1.05), cancer mortality (HR
0.85; 95% CI  0.68–1.06), and cancer incidence (HR  1.07; 95% CI  0.92–1.25) did not differ sig-
nificantlybetweenparticipants allocatedvitaminDand thosenot.All-causemortality (HR1.03; 95%
CI0.94–1.13), vasculardiseasemortality (HR1.07;95%CI0.92–1.24), cancermortality (HR1.13;
95% CI 0.91–1.40), and cancer incidence (HR 1.06; 95% CI 0.91–1.23) also did not differ signif-
icantlybetweenparticipants allocated calciumand thosenot. In aposthoc statistical analysis adjusting
forcompliance, thuswithfewerparticipants, trendsforreducedmortalitywithvitaminDandincreased
mortality with calcium were accentuated, although all results remain nonsignificant.
Conclusions:Daily vitaminDor calcium supplementationdid not affectmortality, vascular disease,
cancer mortality, or cancer incidence. (J Clin Endocrinol Metab 97: 0000–0000, 2012)
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The effect of calciumand/or vitaminDon awide varietyof nonfracture health outcomes is the subject of a
great deal of scientific and lay interest. The recent Institute
of Medicine report on dietary intake requirements sup-
ported a key role for vitamin D and calcium for skeletal
health but did not find conclusive evidence for nonskeletal
benefits (1).
The active metabolite of vitamin D, 1,25-dihydroxyvi-
tamin D3, and its analogs have in vivo anticancer effects,
including inhibition of cellular proliferation, activation of
apoptosis, inhibition of angiogenesis, and potentiation of
cytotoxic drugs (2). Meta-analysis of observational stud-
ies suggests an increased risk of colorectal cancerwith low
vitamin D status (3). Although recently published fol-
low-up data from the Third National Health and Nutri-
tional Examination Survey and the Osteoporotic Frac-
tures in Men Study do not support the hypothesis that
serum 25-hydroxyvitamin D is associated with reduced
cancer mortality (4, 5).
Meta-analysis of randomized controlled trials by Au-
tier and Gandini (6) suggested that vitamin D supplemen-
tation, given mainly for fracture prevention, may reduce
all-cause mortality. In the Framingham Offspring Study
cohort, low vitamin D status was associated with an in-
creased risk of developing cardiovascular disease (7).
However, the Osteoporotic Fractures in Men Study did
not findanassociationbetween low25-hydroxyvitaminD
and subsequent all-cause or cardiovascular mortality, al-
though lower PTH levels appeared protective (5). Accu-
mulating evidence suggests that vitamin D is essential for
normal cardiomyocyte, vascular smooth muscle, and vas-
cular endothelial cell function (8) and may lower blood
pressure in people with hypertension (9).
Many trials of vitamin D supplementation for fracture
prevention have cosupplemented with calcium (10). Cal-
cium supplementationmight reduce the risk of developing
colorectal adenomatous polyps (11). However, although
systematic review evidence from trials suggests that cal-
cium supplementation may lower systolic blood pressure
in people who are hypertensive (12), recently published
meta-analyses have found an increased risk of myocardial
infarctionwith calcium supplementation, with orwithout
vitamin D (13, 14).
The RECORDTrial was a pragmatic, randomized fac-
torial-designed, placebo-controlled, trial of calcium
and/or vitaminD3 supplementation for the secondary pre-
ventionof fragility fractures in 5292older people (15).We
prespecified in our protocol long-term follow-up for sec-
ondary outcomes of mortality due to cardiovascular dis-
ease or cerebrovascular disease and cancer (15).
Subjects and Methods
Participants
The RECORD Trial was based in 21 centers in England and
Scotland. Full details of all themethods can be found in themain
trial report for fracture outcomes (15). Participants were re-
cruited from fracture clinics or orthopedic wards. Inclusion cri-
teria were fragility fracture within the last 10 yr and aged at least
70yr. Exclusion criteriawere cancer likely tometastasize tobone
within the previous 10 yr, bed- or chair-bound before fracture,
abbreviated mental test below 7 (16), fracture associated with
preexisting local bone abnormality, knownhypercalcemia, renal
stone in the last 10 yr, life expectancy less than 6months, known
to be leaving the United Kingdom, taking more than 200 IU (5
g) vitamin D or more than 500 mg calcium in supplements
daily, treatment with fluoride, bisphosphonates, calcitonin, ti-
bolone, hormone replacement therapy, selective estrogen recep-
tor modulators, or any vitamin D metabolite (such as calcitriol)
in the last 5 yr or vitamin D by injection in the last year.
Interventions
Participants were randomized into four equal groups to re-
ceive two tablets dailywithmeals containing a total of 800 IU (20
g) vitaminD3, 1000mg elemental calcium (as carbonate), both
vitamin D3 and calcium, or placebo. Tablets varied in size and
taste, and so each had matching placebos. Calcium and calcium
and vitamin D tablets were large, and those for vitamin D were
small. Placebos matched in size were provided for each of these
three types of tablets. All trial materials were delivered by post
every 4 months.
Outcomes and follow-up
All-cause mortality, mortality due to vascular disease and
cancer, and cancer registrations were prespecified outcomes in
the main trial protocol (http://www.thelancet.com/protocol-re-
views/02PRT-35). This paper reports follow-up mortality data
that had been notified during the trial and within 3 yr of trial
closureaswell as cancernotifications relevant to thisperiod.This
timing was selected because the effects of calcium and vitamin D
maybe lostwithin2yrof cessationof supplementation (17).This
timing was also based on a power calculation of at least 400
cancer registrations at follow-up from the 5292 trial partici-
pants, giving 80% power (P  0.05) to detect an absolute re-
duction of 2% (from 8 to 6%). Data were derived only from the
main cause of death for death registrations, and registrations of
new cancers for all trial participants were collected only through
the national United Kingdom databases of the General Register
of Scotland; the National Health Service Medical Research In-
formation Service, England; and the United Kingdom Associa-
tion of Cancer Registries (www.ukacr.org). The data presented
here were not examined by a trial adjudication committee but
were collected completely independent of the trial. The above
organizations all undertake rigorous quality checks on a regular
basis.
Because the exactmechanisms bywhich calciumor vitaminD
may influence the circulation are unclear, a wide definition from
the International Classification of Diseases was adopted a priori
(ICD codes I00–I99) for total vascular disease deaths. Data are
also presented separately for cardiovascular disease deaths (ICD
I20–I25) and cerebrovascular disease deaths (ICD I60–I69).
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Randomization
Randomization was centralized, computer generated, strati-
fied by center, and minimized by age (under 80 yr or 80 yr and
over), gender, time since fracture (previous 3 months or longer),
and type of enrolling fracture (proximal femur, distal forearm,
clinical vertebral, and other).
Compliance
Compliance was measured by 4-monthly postal question-
naire, where participants were asked how many days of the
last seven they took tablets. A random 10% sample returned
unconsumed tablets for pill counting. In two trial centers, a
sample of 60 participants had blood collected for 25-
hydroxyvitamin D3 measured using straight-phase HPLC at
baseline and 1 yr later (18).
Dietary calcium and vitamin D assessment
Dietary calcium and vitamin D intake were assessed using
food frequency questionnaires, based on Nelson et al. (19) and
the United Kingdom National Diet and Nutrition Survey (20),
respectively, and sunlight exposure by a questionnaire about
time outdoors and season.
Statistical analysis
Survival time was modeled using Cox proportional hazards
regression models. Four outcome survival measures were ex-
plored: time to death, time to death from vascular disease and
cancer (censoring those dying from other causes in each case),
and time to cancer incidence. The explanatory variables in the
models were the treatment group and the variables used formin-
imization at randomization (age, gender, time since fracture, and
type of fracture). The main analyses focused on main effects
reflecting the factorial design: vitamin D3 vs. no vitamin D3 and
calcium vs.no calcium. Interaction between calciumand vitamin
D3 was also tested for.
Two methods of handling the noncompliance were used. First,
intention-to-treat (ITT, patients analyzed as per the treatment they
were randomized to) was used on the complete dataset.
Compliance with trial medication was limited (15). Among
those returningquestionnaires (or after assumingnonresponders
were noncompliers), the rates of pill takers were 67% (54%) at
12 months and 63% (45%) at 24 months. Poorer compliance
with tablets containing calcium (difference 9.4% for all partic-
ipants randomized at 2 yr) appeared to reflect more frequent
decisions to stop because of gastrointestinal symptoms (15). We
therefore undertook a post hoc analysis to explore the effects of
compliance with the treatment regimen on outcome. Compli-
ancewasbasedonpostal data collected2yr after randomization,
when compliers were still taking tablets on 80%of days, and we
used a simple all or nothing definition of compliance for these
analyses. The method of Loeys and Goetghebeur (21) was im-
plemented using the stcomply command in Stata (22). For each
model, hazard ratios (HR) with 95% confidence intervals (CI)
were calculated.
Results
Recruitment and comparability of trial group at
entry
A total of 5292 people, with a mean age of 77 (SD 6)
years joined the trial between February 1999 and March
2002. The four primary trial groupswerewell balanced at
trial entry (Table 1). The median length of follow-up for
the data reported here was 6.2 yr. Participants had poor
TABLE 1. Description of groups at trial entry
Vitamin D3
and calcium
(n  1306)
Vitamin D3
(n  1343)
Calcium
(n  1311)
Placebo
(n  1332)
With
vitamin D3
(n  2649)
Without
vitamin D3
(n  2643)
With
calcium
(n  2617)
Without
calcium
(n  2675)
Age mean (SD) yr 78 (6) 77 (6) 77 (6) 77 (6) 77 (6) 77 (6) 77 (6) 77 (6)
Sex n (%) female 1104 (84.5) 1136 (84.6) 1113 (84.9) 1128 (84.7) 2240 (84.6) 2241 (84.8) 2217 (84.7) 2264 (84.6)
White n (%) 1298 (99.4) 1331 (99.1) 1303 (99.4) 1320 (99.1) 2629 (99.2) 2623 (99.2) 2601 (99.4) 2651 (99.1)
Months since enrolling fracture median(IQR) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
Diabetic n (%) 109 (8.4) 99 (7.4) 111 (8.5) 101 (7.6) 208 (7.9) 212 (8.1) 220 (8.5) 200 (7.5)
Oral hypoglycemics 57 (4.4) 62 (4.6) 59 (4.5) 49 (3.7) 119 (4.5) 108 (4.1) 116 (4.4) 111 (4.1)
Insulin 20 (1.5) 20 (1.5) 27 (2.1) 23 (1.7) 40 (1.5) 50 (1.9) 47 (1.8) 43 (1.6)
Calcium intake, mg/d mean (SD) 818 (355) 813 (359) 814 336) 834 (861) 815 (357) 823 (349) 816 (345) 824 (360)
Vitamin D deficiency risk n (%)
High risk 390 (30.8) 420 (32.4) 390 (31.2) 419 (32.9) 809 (32.0) 810 (31.6) 839 (32.7) 780 (31.0)
Low risk 876 (69.2) 875 (67.6) 862 (68.8) 854 (67.1) 1716 (68.0) 1751 (68.4) 1729 (67.3) 1738 (69.0)
Weight, kg mean (SD) 65 (13) 65 (13) 65 (13) 65 (12) 65 (13) 65 (12) 65 (13) 65 (13)
Current smoker n (%) 158 (12.1) 140 (10.5) 164 (12.5) 156 (11.7) 298 (11.3) 320 (12.1) 322 (12.3) 296 (11.1)
Daily physical activity n (%) 1221 (93.7) 1271 (95.0) 1232 (94.2) 1255 (94.4) 2492 (94.4) 2487 (94.3) 2453 (93.9) 2526 (94.7)
Could walk out of doors unaccompanied
Current use n (%)
T4 117 (9.1) 97 (7.3) 129 (10.0) 91 (6.9) 214 (8.2) 220 (8.4) 246 (9.5) 188 (7.1)
Oral steroids 7.5 mg prednisolone daily 31 (2.4) 18 (1.4) 27 (2.1) 17 (1.3) 49 (1.9) 44 (1.7) 58 (2.2) 35 (1.3)
Thiazide diuretics 258 (20.2) 292 (22.2) 273 (21.4) 288 (22.0) 550 (21.2) 561 (21.7) 531 (20.8) 580 (22.1)
Type of enrolling fracture n (%)
Proximal femur 228 (17.5) 231 (17.2) 222 (16.9) 223 (16.7) 459 (17.3) 445 (16.8) 450 (17.2) 454 (17.0)
Other leg and pelvic 285 (21.8) 255 (19.0) 308 (23.5) 282 (21.2) 540 (20.4) 590 (22.3) 593 (22.7) 537 (20.1)
Distal forearm 452 (34.6) 472 (35.1) 460 (35.1) 462 (34.7) 924 (34.9) 922 (34.9) 912 (34.8) 934 (34.9)
Other arm 339 (26.0) 383 (28.5) 319 (24.3) 362 (27.2) 722 (27.3) 681 (25.8) 658 (25.1) 745 (27.9)
Other 2 (0.2) 2 (0.1) 2 (0.2) 3 (0.2) 4 (0.2) 5 (0.2) 4 (0.2) 5 (0.2)
IQR, Interquartile range.
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vitamin D status at recruitment (25-hydroxyvitamin D 38
nmol/liter in a subgroup from all groups in the trial at
baseline) (11).
Outcomes (Table 2)
Overall, during the trial and 3 yr of follow-up, 1717 of
5292 participants (32.4%) died. The main cause of death
was recorded as vascular disease for 726 participants
(42.3%of deaths) and cancer for 329participants (19.2%
of deaths). Of 5292 participants (12.3%), 653 developed
a new cancer.
Vitamin D (Table 3 and Fig. 1)
In the ITT analysis, 836 participants (31.6%) of 2649
participants allocated vitamin D died compared with 881
of 2643 (33.3%) not allocated vitamin D (HR  0.93;
95% CI  0.85–1.02). The incidence of vascular disease
deaths (HR 0.91; 95%CI 0.79–1.05), cancer deaths
(HR 0.85; 95% CI 0.68–1.06), and participants de-
veloping cancer (HR  1.07; 95% CI  0.92–1.25) did
not differ significantly in the ITT analysis between par-
ticipants allocated vitamin D and those who were not.
Calcium (Table 3 and Fig. 2)
In the ITT analysis, 862 participants (32.9%) of 2617
participants allocated calcium died compared with 855 of
2675 (32.0%) not allocated calcium (HR  1.03; 95%
CI 0.94–1.13). The incidence of vascular disease deaths
(HR 1.07; 95%CI 0.92–1.24), cancer deaths (HR
1.13; 95% CI 0.91–1.40), and participants developing
cancer (HR  1.06; 95% CI  0.91–1.23) did not differ
significantly in the ITT analysis between participants al-
located calcium or those who were not.
TABLE 2. Outcomes according to allocation
Outcome
Vitamin D3
and calcium Vitamin D3 Calcium Placebo
With
vitamin D3
Without
vitamin D3
With
calcium
Without
calcium
n 1306 1343 1311 1332 2649 2643 2617 2675
All new cancer events total 182 187 189 165 369 354 371 352
Breast 20 23 21 16 43 37 41 39
Colorectal 24 17 22 8 41 30 46 25
Lung 10 14 14 18 24 32 24 32
Prostate 8 9 4 8 17 12 12 17
Other 120 124 128 115 244 243 248 239
Participants with cancer events 166 172 163 152 338 315 329 324
1 154 157 140 140 311 280 294 297
2 9 15 20 11 24 31 29 26
3 3 0 3 1 3 4 6 1
All deaths total 415 421 447 434 836 881 862 855
All cancer deaths total 78 73 95 83 151 178 173 156
Breast 7 7 9 4 14 13 16 11
Colorectal 13 7 7 6 20 13 20 13
Lung 14 10 13 21 24 34 27 31
Prostate 2 4 3 3 6 6 5 7
Other 42 45 63 49 87 112 105 94
All vascular disease deaths total 177 173 194 182 350 376 371 355
Cardiovascular 88 74 91 85 162 176 179 159
Cerebrovascular 56 59 54 51 115 105 110 110
Other 33 40 49 46 73 95 82 86
TABLE 3. HR for mortality, vascular disease mortality, cancer mortality, and cancer: ITT analysis
With vitamin D3 or calcium Without vitamin D3 or calcium
HR (95% CI):
ITT estimate P valueEvents
No. of
participants
% with
event Events
No. of
participants
% with
event
Vitamin D3
All deaths 836 2649 31.6 881 2643 33.3 0.93 (0.85–1.02) 0.132
Vascular deaths 350 2649 13.2 376 2643 14.2 0.91 (0.79–1.05) 0.175
Cancer deaths 151 2649 5.7 178 2643 6.7 0.85 (0.68–1.06) 0.157
Cancer incidence 338 2649 12.8 315 2643 11.9 1.07 (0.92–1.25) 0.376
Calcium
All deaths 862 2617 32.9 855 2675 32.0 1.03 (0.94–1.13) 0.460
Vascular deaths 371 2617 14.2 355 2675 13.3 1.07 (0.92–1.24) 0.333
Cancer deaths 173 2617 6.6 156 2675 5.8 1.13 (0.91–1.40) 0.249
Cancer incidence 329 2617 12.6 324 2675 12.1 1.06 (0.91–1.23) 0.485
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We undertook post hoc analyses to examine whether
participants using thiazide diuretics at baseline, which
cause calcium retention, or participants with higher cal-
cium intakes at baseline had increased risk of vascular
disease mortality. There was no evidence of a higher risk
of cardiovascular death in those that were using thiazide
diuretics at baseline (tested for by examining the interac-
tion of thiazide by calcium). Nor was there any evidence
of a higher risk of vascular death in those with a high
baseline intake of calcium at baseline, defined as more
than 800mgaday (tested for by examining the interaction
between calcium intake at baseline and calcium).
Forty-sixnewcolorectal cancerswerediagnosed inpar-
ticipants allocated calcium and 25 in those not allocated
calcium. Twenty participants allocated calcium died of
colorectal cancer compared with 13 participants not al-
located calcium (Table 2).
Analyses adjusted for compliance (Table 4)
In the post hoc analyses adjusted for compliance with
vitamin D, all-cause mortality (HR  0.80; 95% CI 
0.61–1.11), vascular disease mortality (HR 0.76; 95%
CI0.49–1.40), cancermortality (HR0.61; 95%CI
0.37–1.30), and participants developing cancer (HR 
1.24; 95% CI  0.80–2.28) also did not differ signifi-
cantly in response to vitamin D, although all trends were
accentuated compared with the ITT analysis.
Similarly, for calcium in the analyses adjusted for com-
pliance, all-cause mortality (HR 1.21; 95%CI 0.83–
2.05), vascular disease mortality (HR 1.43; 95% CI 
0.75–7.61), and cancer incidence (HR 1.26; 95%CI
0.73–3.26) were not significantly different between those
participants allocated calcium and those not. Again, all
trends were accentuated in this compared with the ITT
analysis. There were insufficient data to provide confi-
dence intervals for cancer mortality.
Discussion
Principal findings for vitamin D
In this older age group at high risk of refracture, daily
800 IU vitamin D3 supplementation was not found to sig-
nificantly reduce all-cause and vascular disease mortality
or cancer incidence or mortality in the ITT analyses. Pre-
viously, we found that vitaminD supplementation did not
affect glycemic control or fracture risk in the RECORD
Trial population (15, 23).
We do not know whether the results reported here
would be found in younger populations, older people
without a history of previous fragility fracture, or very
high-risk populations in nursing homes. In the United
Kingdom, 47%of people aged 45 yr have also been found
to fall below a level for 25-hydroxyvitamin D of 40 nmol/
liter in winter and spring, a level similar to the baseline
level in the RECORD Trial subgroup (24). Thus even
young populations may be at risk at higher latitudes with
little food fortification.
FIG. 2. Cumulative all-cause mortality by allocation to calcium or no
calcium.
FIG. 1. Cumulative all-cause mortality by allocation to vitamin D or no
vitamin D (VitD).
TABLE 4. HR for mortality, vascular disease mortality,
cancer mortality, and cancer: adjusted treatment-received
analysis
HR (95% CI)
Vitamin D vs. no vitamin D
All deaths 0.80 (0.61–1.11)
Vascular deaths 0.76 (0.49–1.40)
Cancer deaths 0.61 (0.37–1.30)
Cancer incidence 1.24 (0.80–2.28)
Calcium vs. no calcium
All deaths 1.21 (0.83–2.05)
Vascular deaths 1.43 (0.75–7.61)
Cancer incidence 1.26 (0.73–3.26)
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Comparison with other studies: all-cause mortality
Autier and Gandini (6) undertook a meta-analysis in
57,311participants of randomized trials of vitaminDsup-
plementationwith orwithout calcium,which included the
RECORDTrial data fromthe initial trial report (15).They
found that the risk ratio (RR) for all-cause mortality was
0.93 (95%CI 0.87–0.99), similar to the point estimate
for the ITT result found here. Vitamin D doses were 300–
833 IU/d, and additional supplementation with calcium
did not appear to influence this result. Most of these trials
were fracture prevention trials.
A recent Cochrane review has examined the effect of
vitaminD onmortality in randomized trials (25). Vitamin
D3 given without calcium was not found to significantly
reduce mortality (RR  0.95; 95% CI  0.82–1.02).
Comparison with other studies: vascular disease
TheWomen’sHealth Initiative (WHI) randomized trial
examined the effect of daily 400 IU vitamin D3 and 1000
mg calcium together for a mean of 7 yr in 36,282 post-
menopausal women (mean age 62 yr) on myocardial in-
farction and coronary heart disease death (HR  1.04;
95%CI 0.92–1.18) and stroke (HR 0.95; 95%CI
0.82–1.10) (26). Baseline 25-hydroxyvitamin D levels in
two subgroups were around 47 nmol/liter (27). WHI also
foundno statistically significant effect of supplementation
on systolic or diastolic blood pressure (28). However, the
effects of vitamin D could not be disassociated from those
of calcium, and 54% of women were taking their own
calcium supplements at randomization (14). For the
women inWHI, who did not take calcium supplements at
randomization, calcium and vitamin D supplementation
was associated with an increased risk of cardiovascular
events (14). Trial-level meta-analysis, includingwomen in
WHI who did not take calcium supplements at random-
ization, also suggests increased cardiovascular eventswith
calcium and vitamin D given together (14).
Trivedi et al. (29) randomized 2686 men and women
(mean age 75 yr) to 100,000 IU vitamin D3 or placebo
every 4 months for 5 yr. Vitamin D only supplementation
was associated with a decrease in vascular disease mor-
tality (age-adjusted RR  0.84; 95% CI  0.65–1.10).
Baseline vitamin D status was not assessed.
Comparison with other studies: cancer
The WHI trial also examined the effect of calcium and
vitamin D on the risk of developing cancer (HR  0.98;
95%CI 0.91–1.05), invasive breast cancer (HR 0.96;
95% CI  0.85–1.09), or invasive colorectal cancer
(HR  1.08; 95% CI  0.86–1.34) (30, 31). Cancer
deaths (HR  0.89; 95% CI  0.77–1.03), deaths from
breast cancer (HR  0.99; 95% CI  0.55–1.76), and
deaths from colorectal cancer (HR  0.82, 95% 0.52–
1.29) were not significantly reduced (30, 31). There is
evidence to suggest that coadministration of estrogen in
WHImay havemodified the effect of calcium and vitamin
D on colorectal cancer risk (32).
Trivedi et al. (29) also found thatmortality from cancer
was reduced, although not significantly (age-adjusted
RR  0.86; 95% CI  0.61–1.20).
Lappe et al. (33) randomized 1179women (median age
67 yr, baseline 25-hydroxyvitamin D 72 nmol/liter) to
1100 IU vitamin D3 and 1500mg calcium, calcium alone,
or placebo for 4 yr and reported a reduced risk of cancer
on calcium and vitamin D compared with placebo group,
whichhadahigher than expected rateof cancer.However,
the methods and analysis of this trial have been criticized,
and reanalysis suggests that calciumbutnot vitaminDwas
associated with reduced cancer risk (6).
Principal findings for calcium
Daily supplementation with 1000 mg calcium carbon-
ate was not found to significantly affect cancer incidence
or mortality, overall mortality, or vascular mortality.
Comparisons with other studies
In an individual patient data meta-analysis, which in-
cludes RECORDTrial data collected during the trial, Bol-
land et al. (14) reported a significantly increased risk of
myocardial infarction with supplemental calcium (HR 
1.31;95%CI1.02–1.67),whichdidnot appear to relate
to the form of calcium supplement (mostly calcium car-
bonate or citrate). We examined all vascular mortality,
which increased our statistical power.Our results are con-
sistentwith the Bollandmeta-analysis.We found trends in
the same direction, especially in the analysis adjusted for
compliance, with confidence intervals overlapping those
in the Bolland meta-analysis.
A Cochrane systematic review (11) based on two ran-
domized trials with 1346 participants with previous colo-
rectal adenomas concluded that calcium supplementation
of 1200–2000 mg/d over 3–4 yr reduced recurrence of
adenomas. In the RECORD Trial, we did not have suffi-
cient statistical power to evaluate the effect of calcium on
colorectal cancer, but events and deathswere higher in the
calcium-supplemented group. A New Zealand trial re-
ported that supplementation with 1000 mg calcium over
5 yr in 1471 women (mean age 74 yr, baseline 25-hy-
droxyvitamin D 52 nmol/liter) did not reduce the inci-
dence of any cancer (34).
Analyses adjusted for compliance
Our post hoc analyses adjusted for compliance did not
significantly change our findings, although all trendswere
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accentuated. Compliance was based on the details pro-
vided by participants in postal questionnaires rather than
tablet counting for all participants. The pragmatic nature
of the RECORD Trial, without frequent follow-up visits
and tablet counting reflects real-world practice, where
compliance with tablet taking in older people, including
for osteoporosis treatment, is frequently poor (35).Owing
to the staggered nature of recruitment, 5292 participants
were in the trial for 2 yr, 4090participantswere in the trial
for 3 yr, and 1979 were in the trial for 4 yr (these figures
include all people randomized). The worst-case scenario
for compliance, assuming that people failing to return
questionnaires did not take any tablets, indicated tablet
taking on more than 80% of days for 45% at 2 yr, 35%
at 3 yr, and 25% at 4 yr.
Our analyses adjusted for compliance had reduced sta-
tistical power, and we were unable to provide CI for cal-
cium and cancer mortality. Adjusting for compliance also
made no difference to the results for fracture from the
RECORD Trial (data not shown), which could also have
been influenced by inadequate statistical power.
Poorer compliance with calcium-containing tablets ap-
peared to partly relate to a variety of gastrointestinal
symptoms rather than the larger size of calcium tablets
(15). Compliance with the larger placebo calcium tablets
was only 2% less than with the small placebo vitamin D
tablets.
Future trials of vitamin Dwill need to address the issue
of compliance. Intermittent oral vitaminDdosing, such as
usedbyTrivedi et al. (29),might improve compliancewith
vitamin D, and higher doses may help to circumvent poor
compliance. However, annual dosing with large doses of
vitamin D was recently found to increase the risk of falls
and fractures in an Australian trial by Sanders and col-
leagues (36).
The RECORD Trial was able to examine outcomes in
response to calcium or vitamin D supplementation sepa-
rately in the same trial. The blinded, placebo-controlled
nature of the trial and the independent collection of the
data presented here through national databasesmean that
bias in data collection is unlikely.
Participants were older and had poorer vitamin D sta-
tus at recruitment than many other trials (25-hydroxyvi-
taminD 38 nmol/liter at baseline) (15) somight have been
more likely to benefit from vitamin D supplementation.
25-Hydroxyvitamin D was recorded in only a very small
subgroup of 60 participants in the RECORD Trial.
These participants may not have been representative of
the wider trial population, because they had agreed to
extra study visits and may thus have been fitter than the
general RECORD population. However, with such a
large trial, it is likely that baseline 25-hydroxyvitamin D
status was very similar between the groups. Supplemen-
tation achieved a level of 25-hydroxyvitamin D of 62
nmol/liter in this subgroup (15), a level that could be sub-
optimal (37).
In the United Kingdom, cod liver oil is a common over-
the-counter supplement (also containing retinol) pur-
chased by older people for themselves. In the RECORD
Trial, over-the-counter use of up to 200 IU/d (5 g) of
vitamin D was permitted, and 17% of RECORD partic-
ipants reported using cod liver oil at recruitment, with
numbers balanced between groups. Over-the-counter use
of calcium is, however, rare in the United Kingdom, and
only 1.5% of RECORD participants reported using cal-
cium at baseline (permitted use up to 400 mg/d). Data on
calcium and vitamin were not collected during the open
follow-up period. But in an open trial run in parallel with
the blinded part of the RECORD Trial (38), no person
reported purchasing calcium or vitamin D supplements,
and only one person was prescribed vitamin D by their
doctor, of a total number of 180 participants in the trial.
Because RECORD found no significant effect on frac-
tures, we think it is unlikely that substantial numbers of
participantswouldhave started touse supplements during
the open period of follow-up.
Our results add to the body of evidence on nonskeletal
benefits from supplementation with vitamin D and cal-
cium and are consistent with the view that, at least for
vascular disease and cancer, conclusive evidence for such
benefits is absent.
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